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IN has been shown to interact with a number of cellular and viral proteins during the integration
process. Disruption of these important interactions could provide a mechanism for allosteric inhi-
bition of IN. We present the highest resolution crystal structure of the IN core domain to date.
We also present a crystal structure of the IN core domain in complex with sucrose which is bound
at the dimer interface in a region that has previously been reported to bind integrase inhibitors.
Structured summary:
MINT-7713125: IN (uniprotkb:P04585) and IN (uniprotkb:P04585) bind (MI:0407) by X-ray crystallogra-
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HIV integrase (IN) is one of the three enzymes encoded in the
HIV genome. IN mediates the retroviral process of integration–
insertion of the proviral DNA into that of the host cell [1]. IN acts
minimally as a pair of homodimers [2] and catalyzes two reactions:
30-processing, where two bases are removed from the blunt-ended
proviral DNA, and strand transfer, where each end of the proviral
DNA is covalently bonded to the host DNA [3]. The essential nature
of integration in HIV replication makes IN a prime target for anti-
HIV drug discovery.
After a long period of development, the ﬁrst IN inhibitor ralte-
gravir [4] is being successfully applied in the clinic [5,6]. Raltegra-
vir is believed to act through interaction with the IN active site and
a coordinated metal ion, located in the core domain, and the bound
viral DNA [7,8]. A common problem with drugs targeting HIV is the
rapid development of mutations in the HIV genome which dimin-
ish their efﬁcacy. Already such mutations have arisen for IN thatchemical Societies. Published by E
ratory, St. Vincent’s Institute,
+61 3 94162676.
edu.au (M.J. Scanlon), mpar-confer resistance to raltegravir. Moreover many of these mutations
show cross resistance proﬁles to elvitegravir, a second IN inhibitor
in phase III clinical trials [8]. Taken together this suggests that
modulation of IN at sites other than the active site would be desir-
able as this would lessen the possibility of cross resistance. It is
becoming increasingly clear that during the process of viral repli-
cation IN also makes functional interactions with a number of viral
and host proteins. Targeting these interactions raises the prospect
of additional approaches to the treatment of HIV. This proposition
for IN has been discussed by a number of authors [9–14] and the
approach of developing drugs that do not target the active site of
an enzyme has already proven successful for drugs targeting HIV
reverse transcriptase [15].
The crystal structures of truncated IN proteins (INCORE [16–26],
INCORE+C [19,27,28], INCORE+N [29,30]) have been determined but no
structure of the full length enzyme or IN with viral DNA is avail-
able. NMR structures of the isolated N-terminal [31–33] or C-ter-
minal [34,35] IN domains have also been reported. Only a small
number of ligands have been observed by crystallography to bind
to IN and unfortunately, in all cases, the observed ligand orienta-
tions are perturbed by crystal contacts with either a neighboring
protomer or a crystallographically related ligand molecule.
The best known IN complex contains the diketo-acid inhibitor,
1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenonelsevier B.V. All rights reserved.
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bound orientation is strongly perturbed by interaction with a sec-
ond ligand molecule. Two tetraphenyl arsonium compounds have
also been reported to interact with the lens epithelium-derived
growth factor (LEDGF) binding site, although these ligands also
make contact with adjacent protomers in the crystal lattice [24].
The naphthalenedisulfonic acid Y3, an inhibitor of strand transfer
and 30-processing has been observed to bind to the closely related
avian sarcoma virus IN (ASV IN) near residues 145–152 (equivalent
to residues 140–147 in HIV-1 IN) which form a ﬂexible surface loop
adjacent to the active site [26]. In the ASV IN-Y3 complex two sym-
metry-related ligands bind in close proximity to each other and
may not represent the biologically bound orientation of the mole-
cule. The absence of unperturbed ligand complexes is a signiﬁcant
impediment to the development of drugs that target this enzyme.
The best described IN–protein interaction for IN is with the hu-
man cellular protein, LEDGF [25,29,36–41] which has been charac-
terized biochemically and by X-ray crystallography. LEDGF binds
to IN with the principal contact being a pocket at the IN dimer
interface. The IN binding domain (IBD) of LEDGF has been crystal-
lized bound to the INCORE [25] and more recently to both a two do-
main fragment of HIV-2 INCORE+N [29] and maedi-visna virus (MVV)
INCORE+N [42] where the IBD domain makes additional contacts
with the N-terminal domain of IN. A variety of other cellular bind-
ing partners for IN have been identiﬁed, including transportin 3
(TNP03) [43], embryonic ectoderm development (EED) protein
[44,45], SNF 5 [46–48] and the C-terminal domain of nucleoporin
153 [49]. IN has also been shown to directly interact with HIV re-
verse transcriptase [50–52] and more speciﬁcally Wilkinson et al.
[50] mapped the residues involved in this interaction to the C-ter-
minal domain of IN using a series of heteronuclear single quantum
coherence (HSQC) NMR experiments. At present, apart from LEDGF
and reverse transcriptase, the nature of the IN–protein interactions
have not been characterized in detail.
In spite of this, several sites on IN have been identiﬁed as poten-
tial mediators of protein–protein interactions including the LEDGF
binding site [53], the C-terminal domain [50] and a putative nucle-
ar localization sequence between residues 161–173 [54]. One po-
tential allosteric binding site is a pocket formed at the dimer
interface near amino acid residue K173. This pocket has been iden-
tiﬁed as a site of inhibitor binding by several research groups [12–
14]. Shkriabai et al. [14] used afﬁnity acetylation and mass spec-
trometry to identify this pocket as the binding site of a chicoric
acid analogue and more recently showed that the compound
modulates dynamic interactions between IN subunits in a dose
dependent manner [13]. Du et al. [12] identiﬁed a bis-1-pyrrolidi-
neacetamide compound that competitively inhibited IN binding to
viral DNA. Molecular docking was used to propose a binding orien-
tation, which was corroborated by site-directed mutation of resi-
dues in the proposed binding pocket.
In this work, we describe the characterization of a reported
binding site in the HIV-1 IN core domain containing a bound mol-
ecule of sucrose and present a crystal structure of the HIV-1 IN core
domain to a higher resolution than previously published. The su-
crose binding site represents a potential target for the develop-
ment of allosteric inhibitors of HIV replication.2. Materials and methods
2.1. Mutagenesis
A truncated HIV-1 IN50-212 construct of similar sequence to the
NL43 strain was cloned into the Nde1 and Xho1 restriction sites of
pET28b+ (Novagen). This construct expressed in the IN50-212 do-
main containing an N-terminal 6-histidine (H6) tag followed by athrombin cleavage site. The solubilizing mutations C56S, W131D,
F139D and F185H [19] were introduced into the IN50-212 sequence
and this clone, H6-IN50-212, was used for protein expression and
puriﬁcation. These point mutations signiﬁcantly improve solubility
whilst retaining integrase activity in vitro ([19] and unpublished
results). In addition HIV-1NL43 containing the F185H [55] or C56S
[56] mutations in IN exhibited similar replication proﬁles to wild
type HIV-1NL43 in cells.
2.2. IN expression and puriﬁcation for crystallization
Escherichia coli containing the H6-IN50-212 construct was cul-
tured in Terriﬁc Broth media containing 30 lg ml1 kanamycin.
When OD600 reached 0.6 expression was induced using 0.5 mM
IPTG overnight at room temperature. The cells were harvested by
centrifugation for 20 min at 6000g and pellets were resuspended
in 50% Bugbuster (Novagen) and 50% Buffer A (25 mM HEPES pH
8.0, 0.5 M sodium chloride, 5 mM imidazole, 5 mM dithiothreitol
(DTT), 10% (v/v) glycerol). The cells were incubated on ice for
45 min before debris was removed by centrifugation at 30 000g
for 30 min. The supernatant was ﬁltered through a 0.45 lm Milli-
pore ﬁlter and loaded onto a nickel IMAC sepharose column (GE
Healthcare) column. H6-IN50-212 was eluted using an imidazole gra-
dient against a solution containing 25 mM HEPES pH 8.0, 0.5 M so-
dium chloride, 1 M imidazole, 10% (v/v) glycerol and 1 mM DTT.
Fractions containing H6-IN50-212 were pooled and dialyzed over-
night against 25 mM HEPES pH 8.0, 0.5 M sodium chloride, 5 mM
imidazole, 10% (v/v) glycerol and 1 mM DTT. The N-terminal His6
tag was removed by adding calcium chloride to 2 mM followed
by the addition of thrombin (Sigma) and incubation on ice. After
90% of the protein was cleaved (monitored by SDS gel electropho-
resis) the protein sample was passed over a benzamidine-sephar-
ose column (GE Healthcare). The ﬂow through was collected and
then passed over another Ni2+ IMAC column and the ﬂow through
containing IN50-212 lacking the N-terminal His6 tag was collected.
This protein was buffer exchanged into 25 mM HEPES pH 6.5,
0.5 M sodium chloride and 5 mM DTT and concentrated to 7–
10 mg ml1 using Vivaspin centrifugal concentrators (Sartorius)
with a 5000 MWCO and then used for crystallization.
2.3. Crystallization
Brieﬂy, 2 ll of 8 mg ml1 IN50-212 protein solution was mixed
with an equal volume of reservoir solution (1.8 M ammonium sul-
fate, 0.15 M sodium citrate pH 4.6 and 5 mM cadmium chloride).
Crystallization was performed by the hanging drop vapor diffusion
method [57] at 293 K. Crystals appeared overnight and grew to
typical dimensions of approximately 0.3 mm  0.2 mm  0.1 mm.
2.4. Data collection, structure determination and reﬁnement
Prior to freezing in liquid nitrogen, crystals were soaked in a
solution containing mother liquor and either 20% (v/v) glycerol
(INGOL) or 25% (w/v) sucrose (INSUC) for several minutes. In the case
of INGOL, cadmium chloride was omitted from the cryoprotectant
solution. Diffraction data for the IN50-212 crystals were collected
at 100 K on the 14 BMC beamline or 23 ID-D beamline at the Ad-
vanced Photon Source (Chicago, USA). Data were indexed using
MOSFLM [58] and scaling was performed using SCALA [59] in the
CCP4 interface [60]. Initial phases were determined using AMoRe
[61] with the unliganded HIV-1 core domain (PDB ID: 1EXQ [19])
as the search model. Model building and reﬁnement were com-
pleted using Coot [62], Refmac5 [60] and Phenix [63]. The INGOL
structure was reﬁned using anisotropic temperature factors. The ﬁ-
nal statistics of reﬁnement are summarized in Table 1. The models
were analyzed with the program PROCHECK [64] which showed
Table 1
Summary of X-ray data processing and reﬁnement statistics.
Data collection INGOL INSUC
Wavelength (Å) 0.90 1.00
Temperature (K) 100 100
Maximum resolution (Å) 1.4 2.0
Space group P212121 P212121
Unit-cell (Å) a = 59.6, b = 62.4,
c = 81.1




754 279 (115 695) 149 441 (21 613)
No. of unique reﬂections 60 131 (8679) 20 793 (2979)
Completeness (%) 99.9 (100.0) 100.0 (100.0)
Rmerge (%)a 11.2 (43.9) 9.0 (41.0)
Mean I/r(I) 15.2 (6.6) 12.7 (4.4)
Multiplicity 12.5 (13.3) 7.2 (7.3)
Wilson hBi (Å2) 11.1 24.2
Reﬁnement
Maximum resolution (Å) 1.4 (1.48–1.4) 2.0 (2.1–2.0)
No. reﬂections used 56 999 20 741
No. reﬂections used for
Rfree
3064 1064
Rfree (%) 23.6 24.6
Rfactor (%) 20.3 19.8
No. protein atoms 2492 2332
No. sucrose atoms – 46
No. sulfate ions 3 2
No. cadmium ions – 4
No. water molecules 335 84
R.M.S.D. bond angles () 2.1 1.1
R.M.S.D. bond lengths (Å) 0.02 0.01
Average B-factors (Å2)
Protein atoms 10.3 35.3
Sucrose conformation 1/2 – 36.4/32.3
Water 23.1 36.2
Ramachandran distribution
Most favoured (%) 99.3 98.6
Allowed (%) 0.7 1.4










J. Wielens et al. / FEBS Letters 584 (2010) 1455–1462 1457that their stereochemical quality was similar or better than ex-
pected for structures reﬁned at similar resolution. An omit map
was calculated by performing a round of simulated annealing in
the absence of the sucrose molecules using Phenix [63] and then
superimposing the resultant Fo–Fc map over the ﬁnal INSUC model.
Structure alignments were performed using the align command in
PyMOL [65]. Each protomer of IN was superimposed over chain A
of INGOL using either Ca atoms or all atoms. The coordinates of IN-
GOL and INSUC have been deposited in the Protein Data Bank [66]
with accession numbers 3L3U and 3L3V.
3. Results and discussion
3.1. Expression, puriﬁcation, crystallization and data collection
The core domain of HIV-1 IN containing solubilizing mutations
C56S, W131D, F139D and F185H (IN50-212) was expressed and puri-
ﬁed using methods similar to those described by Chen et al. [19]
Crystals were readily obtained at 295 K using ammonium sulfate
as a precipitant. Crystals were cryoprotected using either a 20%
(v/v) glycerol (INGOL) or a 25% (w/v) sucrose solution (INSUC) prior
to freezing in liquid nitrogen. Both INGOL and INSUC crystallized in
the P212121 space group. INGOL diffracted beyond 1.4 Å resolution
on the 14BM-C beamline and INSUC diffracted beyond 2.0 Å resolu-
tion on the 23ID-D beamline at the Advanced Photon Source (APS,
Chicago, USA). The structures were solved by molecular replace-
ment and the ﬁnal models were reﬁned to Rfactor and Rfree values
of 20.3% and 23.6% respectively for INGOL and 19.8% and 24.6%respectively for INSUC. Data collection, reﬁnement and Ramachan-
dran statistics are shown in Table 1. For both structures, the asym-
metric unit contains two copies of the IN core domain arranged as
a dimer which is accepted as the minimal biologically active unit.
Each INCORE comprises a central ﬁve-strand beta sheet ﬂanked by
six helices with an RNaseH-like fold and is consistent with other
reported crystal structures of this domain [17,19–24].
3.2. Structure of INGOL
The higher resolution of the INGOL structure (1.4 Å) compared
with other published structures (1.6–2.6 Å) provides new insights
into the IN core domain. Twenty seven side-chains were modeled
with two or more alternate conformations (L63, I84, E85, L101,
L102, R107, V113, N144, E157, I182, I191, R199, V201, I203, and
I204 in chain A and L63, L74, V77, K103, K111, V113, S119, K127,
K136, S153, I161 and V165 in chain B) and a 2–3 fold increase in
the number of crystallographic water molecules were observed
(160/protomer compared to 50–100/protomer for other pub-
lished IN structures). Of the alternate conformations the hydropho-
bic residues (L63, L74, V77, I84, L101, L102, V113, I161, I182, I191,
V201, I203, and I204) are mostly buried and involved in Van der
Waals contacts. R107, E85 and K103 are located at the dimer inter-
face and are involved in contacts between protomers. K111, K127,
K136 and N144 are solvent exposed and make contacts with a
neighboring IN molecule in the crystal lattice. The side-chain of
E157 is either directed towards the solvent or makes a hydrogen
bond with the H183 side-chain. A comparison with published IN
crystal structures showed that the overall fold of the core domain
was conserved (R.M.S.D. of 0.6 Å2 (range 0.4–1.0 Å2) using 113 Ca
atoms or average R.M.S.D. of 0.8 Å2 (range 0.6–1.0 Å2) using all
atoms (820 atoms)).
A ﬂexible loop (residues 140–149) ﬂanking the catalytic D, D, E
motif is traceable in chain A (Fig. 1). This loop is typically disor-
dered or contacting residues from a neighboring protomer in the
crystal lattice in other published IN structures. Contacts between
this loop and neighboring IN molecules in the crystal lattice were
inspected. Only residues 140–144 were found to be involved in
crystal contacts. Residues in this loop are highly conserved and
are important for IN function [67]. In chain A of the INGOL structure,
the mobile loop is in an open conformation and folds back on the
protein. Interestingly neither Q148 nor E152 are located in the ac-
tive site region, instead these important residues are both pointing
away from this region and towards the solvent. This conformation
may represent the orientation of IN prior to viral DNA binding. In
contrast residues 141–148 could not be modeled into the electron
density for chain B. Despite several attempts to get suitable dif-
fracting crystals in the presence of Mg or Mn ions, a metal ion coor-
dinating to D64 and D116 was absent from the structure; rather
D64 is orientated to form a hydrogen bond with N155 which in
turn causes a small distortion in the b2 strand. D116 interacts with
the backbone nitrogen of G118 and several crystallographic water
molecules.
3.3. Structure of INSUC
For the INSUC structure, a sucrose molecule from the cryoprotec-
tant was identiﬁed at the interface between the two IN monomers
comprising residues E87, V88, I89, P90, E96, Y99, F100, K103 and
K173 of chain A and the same residues in chain B (Fig. 2A). The su-
crose binding pocket is ﬂanked by the two LEDGF binding pockets
in the IN dimer and is adjacent to the active site D, D, E residues
(Fig. 2B). Due to the symmetry of the binding site, sucrose is found
in two overlapping, alternate orientations which were each mod-
eled to bind at 50% occupancy based on difference maps. An omit
map calculated by completing a round of simulated annealing in
Fig. 1. Crystal structure of INGOL solved to 1.4 Å. (A) INGOL shown in cartoon with protomers colored green and blue respectively and residues 140–149 in chain A colored
orange. Selected residues in the active site and the ﬂanking loop are shown in stick. (B) A Connolly surface [77] applied over residues in INGOL with the exception of residues
140–149 which are shown in stick. Crystallographic waters are shown as spheres. Hydrogen bonds between the loop, crystallographic waters and protein are shown as
dashed lines.
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model (Fig. 2C). Each of the sucrose conformations makes a net-
work of hydrogen bonds with the protein directly, through interac-
tions with the side-chain atoms of residues E96, K103 and K173
and the backbone of V88 from both monomers, and indirectly
through the crystallographically observed water molecules; HOH
11, 25, 29, 62, 66, 82 and 84 (shown in Fig. 2D, E and described
in Table 2). Water molecules HOH 11 and HOH 25, and HOH 62
and HOH 82 occupy equivalent positions in each monomer
whereas the other water molecules in the binding site (HOH 29,
HOH 66 and HOH 84) do not. These latter water molecules have
high B-factors. There was weak evidence for symmetry equivalent
waters for HOH 29, HOH 66 and HOH 84 at low sigma levels in the
2Fo–Fc map; however, after several test model building and reﬁne-
ment cycles electron density around the waters did not improve
and B-factors remained high. For this reason these water molecules
were not included in the ﬁnal model even at lower levels of occu-
pancy (<50%). HOH 66 and HOH 84 were modeled to have 50%
occupancy which reduced the B-factors of these molecules from
50 Å2 to a level more consistent with the surrounding environ-
ment (30 Å2). From a comparison of this pocket to other pub-
lished IN crystal structures, we found that the sucrose binding
site typically contains a network of water molecules (18 in the IN-
GOL structure) which are displaced upon sucrose binding, with the
exception of HOH 11 and HOH 25, and to a lesser extent HOH 62
and HOH 82 which tend to be conserved (data not shown). These
four water molecules are stabilized through multiple hydrogen
bonds with protein residues in the pocket in the absence of sucrose
but also have a signiﬁcant role in sucrose binding.
Interactions between the sucrose and IN were dominated by
hydrogen bonding with 18 hydrogen bonds between the protein
and crystallographic water molecules and Van der Waals contacts
with Y99, K173 and E87. The average B-factors of atoms in the su-
crose conformers (36 and 32 Å2 respectively) were consistent with
surrounding residues (32 Å2). The position of residues in the su-
crose binding pocket was compared to INGOL and with the excep-
tion of the solvent exposed K173 side-chains which move to
form hydrogen bonds with the sucrose molecule there were no
other signiﬁcant changes observed in residue positions.Of the residues that make up the sucrose binding pocket, E87,
V88 and I89 are invariant and P90, E96, Y99, F100, K103 and
K173 share greater then 98% sequence similarity in samples iso-
lated from patients who are naive to IN inhibitors [67,68] but are
more variable in a sequence alignment of the more distantly re-
lated lentiviral INs (data not shown). Comparison of simian immu-
nodeﬁciency virus (SIV [27] and HIV-2 IN [29] crystal structures
with HIV-1 IN show that the amino acids and orientation of the
residues in the site are conserved with the exception of E96 which
is a glutamine, Y99 which is a leucine and K173 which is a gluta-
mate in the HIV-2 and SIV structures. The site has a similar shape
but residues are less conserved in the Rous sarcoma virus (RSV)
[28] and Maedi-visna virus (MVV) [42] IN structures. The equiva-
lent sucrose binding pocket in the RSV and MVV IN structures both
contain more polar residues.
Attempts to determine an IC50 for integration in an assay similar
to that described by Ovenden et al. [69] showed that sucrose
exhibited no inhibition activity at the maximum tested concentra-
tion of 10 mM. Sucrose also failed to show afﬁnity for IN50-212 in
saturation transfer difference (STD) and HSQC NMR experiments
at a concentration of up to 100 mM (data not shown). The concen-
tration of sucrose in the cryoprotectant drop was 700 mM. We
propose that sucrose is a speciﬁc, low afﬁnity ligand with an afﬁn-
ity greater than 100 mM. The lack of inhibition and afﬁnity was
surprising considering the large number of hydrogen bonds that
sucrose makes with IN.
To try and understand why no binding afﬁnity was observed we
compared the conformation of sucrose in our structure to that of
the solid state sucrose structure [70] and to other protein–sucrose
complexes in the Protein Databank [66] to see if it was in a high
energy state. In the solid state structure [70], the glucosyl and
fructosyl rings of the sucrose adopt a conformation where the
bulkier polar groups are positioned equatorially which is consis-
tent with our results. Two internal hydrogen bonds between the
fructosyl-6-OH (donor) and glucosyl-2-OH (acceptor) and the
fructosyl-6-OH and glucosyl-O were observed that were not pres-
ent in our sucrose conformation however these are replaced by
water-mediated hydrogen bonds in an aqueous environment
[71,72] which is consistent with our results. Other polar groups
Fig. 2. Sucrose bound to the HIV-1 IN core domain. (A) Location of the sucrose conformers at the IN dimer interface. IN monomers are colored grey and yellow. (B) Relative
location of the sucrose binding pocket to the D, D, E active site residues (red) and residues involved in binding LEDGF (orange). Arrows indicate the channels between the
LEDGF and sucrose binding pockets. (C) Stereo diagram of Fo–Fc omit map at 3r around the two alternate sucrose orientations (green). (D and E) Stereo diagram of the
hydrogen bonding network between alternate sucrose conformations and IN (blue or grey dashed lines). Residues within 5 Å of the sucrose are shown in stick.
Crystallographic water molecules involved in the interactions are shown as spheres.
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Table 2
Direct and solvent-bridged hydrogen bonding interactions between sucrose oxygen atoms and the protein binding site.
Sucrose atom Sucrose alternative conformation 1 Sucrose alternative conformation 2
H-bond partner Water mediated H-bond H-bond partner Water mediated H-bond
O60 O V88 (B) (2.8 Å) O V88 (A) (2.8 Å)
HOH 82 (2.6 Å) OE1 E87 (B) (2.4 Å) HOH 62 (2.7 Å) OE1 E87 (A) (2.4 Å)
OH Y99 (A) (2.4 Å) OH Y99 (B) (2.5 Å)
N V88 (B) (3.2 Å) N V88 (A) (3.0 Å)
O V88 (B) (3.6 Å) O V88 (A) (3.4 Å)
O40 OE1 E96 (A) (3.5 Å) OE1 E96 (B) (3.5 Å)
OE2 E96 (A) (3.4 Å) OE2 E96 (B) (3.8 Å)
NZ K173 (B) (3.7 Å) NZ K173 (A) (2.9 Å)
HOH 66 (2.9 Å) NZ K173 (B) (2.8 Å) HOH 84 (3.2 Å) OE2 E96 (B) (2.9 Å)
OE2 E96 (A) (3.1 Å)
O30 OE1 E96 (A) (3.1 Å) OE1 E96 (B) (3.09 Å)
HOH 29 (2.5 Å)
O10 NZ K103 (A) (2.5 Å) NZ K103 (B) (2.5 Å)
HOH 11 (3.3 Å) OE1 E96 (A) (2.6 Å) HOH 25 (3.5 Å) OE1 E96 (B) (2.7 Å)
O E96 (A) (2.7 Å) O E96 (B) (2.8 Å)
O1 HOH 29 (3.5 Å) O30 SUC (2.5 Å) HOH 29 (3.5 Å) O30 SUC (2.5 Å)
O2 SUC (2.9 Å) O2 SUC (2.9 Å)
O2 O V88 (B) (3.7 Å) O V88 (B) (3.5 Å)
NZ K173 (A) (2.9 Å)
HOH 29 (2.9 Å) O30 SUC (2.5 Å)
O1 SUC (3.4 Å)
O3 NZ K173 (A) (2.6 Å)
HOH 84 (2.7 Å) OE2 E96 (B) (2.8)
O4 OE1 E96 (B) (2.8 Å) OE1 E96 (A) (2.6 Å)
OE2 E96 (B) (3.5 Å) OE2 E96 (A) (3.3 Å)
HOH 29 (2.9 Å)
O5 NZ K103 (B) (3.5 Å) NZ K103 (A) (3.3 Å)
O6 NZ K103 (B) (3.3 Å) NZ K103 (A) (3.2 Å)
HOH 25 (2.7 Å) OE1 E96 (B) (2.7 Å) HOH 11 (2.7 Å) OE1 E96 (A) (2.6 Å)
O E96 (B) (2.8 Å) O E96 (A) (2.7 Å)
1460 J. Wielens et al. / FEBS Letters 584 (2010) 1455–1462in the solid state structure adopt a conformation to maximize
interactions with neighboring molecules in the crystal lattice.
Examples of protein crystal structures containing sucrose included
amylosucrase (PDB ID: 1MW1, [73]), DNA polymerase I (PDB ID:
3EYZ, unpublished results), beta lactamase (PDB ID: 1LOG, [74])
and the HIV-1 envelope protein GP120 (PDB ID: 2NXZ, [75]). In
each case the conformation of the sucrose rings was consistent
with our structure and that of the solid state structure. In addition
the torsion angle between the two sugar rings was consistent in all
of the structures.
In the protein–sucrose complexes the sucrose binding site
tended to be hydrophilic and extensive hydrogen bonding net-
works were observed between the sucrose and protein residues.
In general, the sucrose rings did not interact directly with protein
residues with the exception of the orange carotenoid protein
(PDB ID: 1M98 [76]). These sites tended to contain a large number
of water molecules which helped to further stabilize binding
though water-mediated hydrogen bonds reminiscent of what
was observed for INSUC. Hydrophobic interactions were minimal.
In summary there was no evidence that the conformation of su-
crose observed in our structure was in a high energy state. Rather
the reason for the lack of observed binding afﬁnity is most likely
due to the high energy required to desolvate the sucrose polar
groups, i.e. desolvation of the hydroxyl groups will incur an enthal-
pic penalty that is not compensated for by the formation of favor-
able bonds with the protein.
We next asked the question what is the importance of this pock-
et and could it potentially be a site for the development of allosteric
IN inhibitors. The sucrose binding pocket is located about 10 Å from
the LEDGF binding site. It has been observed that the IN mutant
L172A/K173A fails to interact with LEDGF even though the
LEDGF-IN crystals did not show contact beyond H171 [25], suggest-
ing some interaction between the pockets. Applying a Connolly sur-
face [77] over the protein reveals a channel between the sucrose
and LEDGF binding pockets (Fig. 2B, arrows). This channel is posi-tioned over Y99 and is ﬂanked by residues E96, Q95, K173 and
H171. It could be exploited for the development of inhibitors tar-
geting LEDGF and provide a method for allosteric inhibition of IN.
The sucrose binding pocket has been previously identiﬁed by
two research groups as a binding site for inhibitors of IN. Du
et al. [12] identiﬁed the symmetrical compound 1-pyrrolidineace-
tamide, N,N0-(methylene-di-4,1-phenylene) bis-1-pyrrolidineace-
tamide as an IN ligand using surface plasmon resonance (SPR).
The compound was found to competitively inhibit DNA binding
to IN50-212 and full length IN (residues 1–288) and to inhibit HIV-
1 IIIB replication with an EC50 of 41 lM in C8166 cells. The binding
site of the inhibitor was located using mutagenesis and found to
involve residues K103, K173 and T174. Shkriabai et al. [14] also
identiﬁed this region as the binding site of a largely symmetrical
bis-caffeoyl derivative, methyl N, O-bis(3,4-diacetoxycinnamoyl)-
D-serinate. This compound exhibited an IC50 of 3 lM in both an
in vitro 30-processing and strand transfer IN assay [78]. Speciﬁcally
they used mass spectrometry to identify the transfer of an acetyl
group from the compound to K173. The current structure of INSUC
provides a description of protein–ligand interactions in a pocket
that has been identiﬁed as a binding site for IN inhibitors. These
details provide a means to design new inhibitors that are capable
of exploiting some of these interactions and therefore build a lead
with greater afﬁnity.4. Conclusions
We present two crystal structures of the IN core domain; the
ﬁrst, INGOL, is reﬁned to a higher resolution than previously de-
scribed and shows a unique orientation of the functionally impor-
tant ﬂexible loop ﬂanking the active site. The second, INSUC, has a
sucrose molecule bound in a symmetrical binding site at the dimer
interface comprising residues E87, V88, I89, P90, E96, Y99, F100,
K103 and K173 from both monomer chains and characterizes a
J. Wielens et al. / FEBS Letters 584 (2010) 1455–1462 1461previously reported inhibitory binding pocket. This site is one of a
number clefts on the surface of IN and may represent a functional
binding pocket for protein–protein recognition. Although the afﬁn-
ity of the sucrose is low, other inhibitors of HIV replication have
been identiﬁed that bind in this region with higher afﬁnity. The
large number of interactions between sucrose and IN could be used
to develop compounds with better binding afﬁnity.
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